Courtesy of Benzinga.
In a report published Monday, Stifel analyst Brian Klein terminated coverage on Oncolytics Biotech (NASDAQ: ONCY).
In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Oncolytics Biotech Inc. (ONCY). Our most recent rating of Hold should no longer be used as an indicator for the company going forward.”
Oncolytics Biotech closed on Friday at $0.42.
Latest Ratings for ONCY
Date | Firm | Action | From | To |
---|---|---|---|---|
Sep 2013 | Needham | Initiates Coverage on | Buy | |
Mar 2013 | Piper Jaffray | Initiates Coverage on | Overweight | |
Dec 2012 | Bloom Burton & Co. | Downgrades | Buy | Hold |
View More Analyst Ratings for ONCY
View the Latest Analyst Ratings
Posted-In: Brian Klein StifelAnalyst Color Termination Analyst Ratings